Axcella Health (AXLA) Stock Price, News & Analysis

Company Overview

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.36 to $0.51
• 50-Day Range: $0.40 to $4.58
• 52-Week Range: $0.34 to $41.25
• Volume: 6,782 shs
• Average Volume: 267,009 shs
• Market Capitalization: $1.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AXLA Stock Analysis - Frequently Asked Questions

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($10.25) earnings per share for the quarter, topping the consensus estimate of ($11.25) by $1.00.

When did Axcella Health's stock split?

Axcella Health shares reverse split before market open on Tuesday, September 19th 2023.The 1-25 reverse split was announced on Thursday, September 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Axcella Health IPO?

Axcella Health (AXLA) raised $76 million in an IPO on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Axcella Health investors own include Predictive Oncology (POAI), Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Ford Motor (F), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AXLA
• CIK: 1633070
• Web: www.axcellahealth.com
• Phone: (857) 320-2200
• Fax: 617-441-6243
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($19.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -259.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.80
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 2,950,000
• Free Float: 2,883,000
• Market Cap: $1.18 million
• Optionable: Optionable
• Beta: 0.46